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Abstract
Epigenetic modifications are heritable changes in gene expression without changes in DNA sequence. DNA methylation has
been implicated in the control of several cellular processes including differentiation, gene regulation, development,
genomic imprinting and X-chromosome inactivation. Methylated cytosine residues at CpG dinucleotides are commonly
associated with gene repression; conversely, strategic loss of methylation during development could lead to activation of
lineage-specific genes. Evidence is emerging that bone development and growth are programmed; although, interestingly,
bone is constantly remodelled throughout life. Using human embryonic stem cells, human fetal bone cells (HFBCs), adult
chondrocytes and STRO-1+ marrow stromal cells from human bone marrow, we have examined a spectrum of
developmental stages of femur development and the role of DNA methylation therein. Using pyrosequencing methodology
we analysed the status of methylation of genes implicated in bone biology; furthermore, we correlated these methylation
levels with gene expression levels using qRT-PCR and protein distribution during fetal development evaluated using
immunohistochemistry. We found that during fetal femur development DNA methylation inversely correlates with
expression of genes including iNOS (NOS2) and COL9A1, but not catabolic genes including MMP13 and IL1B. Furthermore,
significant demethylation was evident in the osteocalcin promoter between the fetal and adult developmental stages.
Increased TET1 expression and decreased expression of DNA (cytosine-5-)-methyltransferase 1 (DNMT1) in adult
chondrocytes compared to HFBCs could contribute to the loss of methylation observed during fetal development. HFBC
multipotency confirms these cells to be an ideal developmental system for investigation of DNA methylation regulation. In
conclusion, these findings demonstrate the role of epigenetic regulation, specifically DNA methylation, in bone
development, informing and opening new possibilities in development of strategies for bone repair/tissue engineering.
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Introduction
Epigenetic regulation of gene expression is an important
mechanism implicated in cell stemness, differentiation and
function. Epigenetic modifications are heritable changes in gene
expression that are not encoded by the DNA sequence.
Methylated cytosine residues at CpG dinucleotides are commonly
associated with gene repression [1]. In prokaryotes, the major role
of DNA methylation is to protect host DNA against degradation
by restriction enzymes. In contrast, eukaryote DNA methylation
has been implicated in the control of several cellular processes
including differentiation, gene regulation, development, genomic
imprinting, X-chromosome inactivation and suppression of
repetitive element transcription and transposition [2,3,4].
Current research has focused on the role of epigenetic processes
in fetal programming and the potential consequences, including
enhanced susceptibility, to chronic diseases in adulthood [5,6].
Strategic loss of methyl groups during development could lead to
activation of specific genes in the appropriate lineage [7]. In
addition, some of the up-regulated genes are normally exclusively
expressed in terminally differentiated cells [8]. These findings raise
the possibility that DNA methylation contributes to silencing of
tissue-specific genes in non-expressing cells, confirming DNA
methylation to be a global repressor of gene expression [7].
The methylation status of DNA domains appears to be faithfully
propagated during development [9]. The DNA methylation
maintenance enzyme DNA methyltransferase 1 (DNMT1) is
partly responsible for this stability, but there is likely to be another,
as yet unknown, component that regulates this process [7].
Furthermore, inhibition of DNMT1 results in reduced methylation
and activation of target genes.
In contrast, in primordial germ cells, the genome undergoes
extensive demethylation, including the removal of previous parent-
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specific methylation marks regulated by imprinted gene expression
[3]. New imprints occur during gametogenesis, in a parent-of-
origin-specific manner. Within a few days of fertilization, genome-
wide demethylation occurs followed by a wave of de novo
methylation, both of which are resisted by imprinted loci [10].
Subsequently DNA methylation patterns must then be maintained
during the phase of rapid cellular proliferation in fetal and
postnatal development.
Here we provide evidence for epigenetic regulation during fetal
femur development. Human fetal femurs of the age used in this
study contain predominantly epiphyseal chondrocytes surrounded
by a perichondrium/periosteum of an outer fibroblastic layer and,
an inner mesenchymal stem cell layer with osteogenic, chondro-
genic and adipogenic differentiation potential as published by
Mirmalek-Sani and coworkers [11]. Such multipotency confirms
human fetal bone cells (HFBCs) to be an ideal developmental
system for investigation of DNA methylation regulation. In order
to explore a potential link between DNA methylation changes in
gene expression observed during fetal development, we have
selected genes that we have previously reported to be associated
with osteoarthritis (OA) [12,13,14]. Using human embryonic stem
cells (hESCs), HFBCs, adult chondrocytes and a STRO-1+ skeletal
stem cell containing population of adult bone marrow, we have
examined a spectrum of developmental stages of femur develop-
ment.
Materials and Methods
Fetal Sample Procurement
Human fetal femurs were obtained after termination of
pregnancy according to guidelines issued by the Polkinghome
Report and with ethical approval from the Southampton & South
West Hampshire Local Research Ethics Committee. Fetal age was
determined by measuring fetal foot length and expressed in weeks
post conception (WPC). In total 12 samples were used (cultured
and uncultured) with a mean age of 8.361.0 WPC. Skeletal
muscle surrounding the femur was removed in sterile phosphate-
buffered saline (PBS) prior to femur dissection and digestion with
collagenase B overnight. The cell suspension was filtered (70 mm
filter) and collected cells were either directly lysed for nucleic acid
isolation or cultured on tissue culture plastic in a-MEM containing
10% FCS.
Cartilage Procurement and Chondrocyte Isolation
Adult femoral heads were obtained with informed patient
consent and the permission of the Local Ethics Committee
following joint replacement surgery due to OA (n= 13, age
71.668.2 years; 3–5 OARSI score) or due to fracture of the neck
of femur (normal) (n = 15, age 76.8616.5 years) (used as a non-OA
control) [15]. Cartilage was dissected within 6 hours of surgery and
chondrocytes from the surface layer of OA femoral heads or the
deep zone of normal cartilage were isolated, as in previous studies
[15]. The cartilage was cut into small pieces and digested by
sequential treatment with 10% trypsin in PBS for 30 minutes;
1 mg/ml of hyaluronidase in PBS for 15 minutes and finally
collagenase B in DMEM/F12 for 12–15 hours at 37uC.
Bone Marrow Procurement and STRO+ Isolation
Bone marrow was obtained with informed patient consent and
the permission of the Local Ethics Committee following joint
replacement surgery. Marrow cells were isolated from trabecular
bone by suspending in a-MEM. The STRO+ fraction, reported to
contain the skeletal/mesenchymal stem cell population and
osteoprogenitor cells [16,17], was isolated by magnetic activated
cell sorting as previously described [18] using STRO-1 antibody
hybridoma supernatant (hybridoma cell line was a kind gift from
Dr J Beresford, University of Bath). The STRO+ and STRO-
fractions were collected and RNA/DNA isolated immediately
(uncultured) or incubated on tissue culture plastic in basal media
(10% FBS, a-MEM) at 37uC in a humidified incubator, 5% CO2.
Human Embryonic Stem Cell Culture
Hues-7 human embryonic stem cells (hESCs) (D. Melton,
Howard Hughes Medical Institute/Harvard University) were
initially cultured on c-irradiated mouse embryonic fibroblasts
(MEFs) in Knockout DMEM (Invitrogen) supplemented with 10%
knockout serum replacement (Invitrogen), 1 mM L-glutamine
(Invitrogen), 50 mM b-mercaptoethanol (Sigma), 0.1 mM non-
essential amino acids (Invitrogen), 10 ng/ml basic FGF (Peprotech
Ltd, London, UK) and 100 mg/ml penicillin/streptomycin (In-
vitrogen). Subsequent maintenance of hESCs on matrigel coated
(BD Biosciences) tissue culture plastic with 24 hours MEF-
conditioned medium (C.M.) followed. Throughout, hESCs were
incubated at 37uC in atmospheric (,20%) oxygen. RNA and
DNA were isolated from hESCs following a minimum of 3
passages on matrigel coated tissue culture plastic.
DNA and RNA Extraction
Total RNA and genomic DNA were isolated simultaneously
using Qiagen AllPrep DNA/RNA Mini Kit according to the
manufacturer’s instructions. RNA was reverse-transcribed with
avian myeloblastosis virus reverse transcriptase, oligo(dT)15 and
random primers [19].
Quantitative Reverse Transcription-polymerase Chain
Reaction (qRT-PCR)
qRT-PCR was conducted using Power SYBR Green PCR
Master Mix (Applied Biosystems) and ABI Prism 7500 detection
system (Applied Biosystems). Exon-exon boundary primers were
designed with Primer Express 3.0 software (Applied Biosystems)
with the exception of IL1B, which was designed by and purchased
from PrimerDesign Ltd, Southampton, UK. Primer sequences
used were iNOS GAGGAGCAGGTCGAGGACTAT (F),
TCTTCGCCTCGTAAGGAAATAC (R); COL9A1
CCTGGTGCTCTTGGTTTGA (F),
CACGCTCCCCCTTTTCTC (R); MMP13 TTAAGGAG-
CATGGCGACTTCT (F), CCCAGGAGGAAAAGCATGAG
(R); IL1B TGGCAATGAGGATGACTTGTTC (F),
CTGTAGTGGTGGTCGGAGATT (R); osteocalcin GGCAGC-
GAGGTAGTGAAGAG (F), CTCACACACCTCCCTCCT (R);
DNMT1 CAGGCCCAATGAGACTGACA (F),
GTGGGTGTTCTCAGGCCTGTAG (R) and GAPDH
CCAGGTGGTCTCCTCTGACTTC (F), TCATACCAG-
GAAATGAGCTTGACA (R). Samples were run in triplicate,
Ct values were analysed using the 22DDCt method and the
expression of target genes were normalised to GAPDH house
keeping gene expression.
Analysis of DNA Methylation by Pyrosequencing
500 ng genomic DNA was bisulfite treated using EZ DNA
Methylation-GoldTM Kit (Zymo Research Corporation) according
to the manufacturer’s instructions. Promoter regions of interest
were amplified using PlatinumH PCR Normal Supermix or High
Fidelity (Invitrogen) and purity confirmed by agarose gel
electrophoresis. Percentage DNA methylation in the promoter
regions was quantified using pyrosequencing primers designed
with PyrosequencingTM Assay Design Software Ver 2.0 (Qiagen)
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Figure 1. iNOS epigenetic regulation during fetal femur development. A. Human iNOS proximal promoter, each circle represents a CpG site.
B. Relative expression of iNOS in HFBCs cells and adult chondrocytes from healthy and OA patients. C. Methylation status of CpG sites localised at the
transcription start site of iNOS gene in HFBCs and adult chondrocytes. D. Correlation between foot length and CpG sites methylation level. E.
Localization of iNOS in a fetal bone from a 4.5 mm fetal sample. See a higher magnification of the square in F. G. Immunohistochemical localization
of iNOS in a fetal bone from an 8.5 mm fetal sample. See a higher magnification of the square in H.
doi:10.1371/journal.pone.0054957.g001
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Figure 2. COL9A1 regulation during fetal femur development. A. Relative expression of COL9A1 in different HFBCs samples. B. Correlation
between foot length and COL9A1 relative expression. C. Human COL9A1 proximal promoter, each circle represents a CpG site. D. Correlation between
foot length and the percentage of methylation of all the CpG sites localised at the proximal promoter. E. Immunohistochemical localisation of
COL9A1 in a fetal bone from a 4.5 mm fetal sample. See higher magnification in F. G. Localisation of COL9A1 in a fetal bone from an 8.5 mm fetal
sample. See a higher magnification of the square in H.
doi:10.1371/journal.pone.0054957.g002
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Figure 3. Changes in MMP13 expression during fetal femur development. A. Human MMP13 proximal promoter, each circle represents a
CpG site. B. Relative expression of MMP13 in different HFBCs samples. C. Correlation between sample age and MMP13 relative expression. D.
Correlation between foot length and the percentage of methylation of all the CpG sites localised at the proximal promoter. E. Immunohistochemical
localisation of MMP13 in a fetal bone from a 4.5 mm fetal sample. See higher magnification in F. G. Localisation of MMP13 in a fetal bone from an
8.5 mm fetal sample. See a higher magnification of the squares in H and I.
doi:10.1371/journal.pone.0054957.g003
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Figure 4. Absence of considerable changes in IL1B during fetal femur development. A. Relative expression of IL1B in different HFBCs
samples compared to healthy chondrocytes. B. Human IL1B proximal promoter, each circle represents a CpG site. C. Correlation between foot length
and the percentage of methylation of all the CpG sites localised at the proximal promoter. D. Localisation of IL1B in a fetal bone from a 4.5 mm fetal
sample. See higher magnification in E. F. Immunohistochemical localisation of IL1B in a fetal bone from an 8.5 mm fetal sample. See a higher
magnification of the square in G.
doi:10.1371/journal.pone.0054957.g004
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Figure 5. Changes in the methylation status of osteocalcin during fetal femur cell development. A. Osteocalcin promoter methylation
status in embryonic, fetal and adult cells. B. Osteocalcin promoter methylation status in STRO-1+ (skeletal stem cell containing) and STRO-12 fractions
of adult bone-marrow cells. C. Localisation of STRO-1 in a fetal bone from a 6 mm fetal sample. See higher magnification in D–E.
doi:10.1371/journal.pone.0054957.g005
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and PyroMarkTM MD (Qiagen) according to the manufacturer’s
instructions. Primer sequences used were iNOS TTGGATGG-
TATGGGGTGAGTATAAAT (F), CCAATCCCCTCAT-
CAAAAATAACC (R), TTTTAAAACAAAAATAAAAC-
TAAATTCTCT (Seq); COL9A1_1
GTTGTTGTGAGAATTAAATGGTATTAAG (F), ACACC-
CAACAATCATTATTTATCA (R), CCCAACAATCATTATT-
TATC (Seq); COL9A1_2 AGGGATTGAAATTTAGGTTGAT
(F), AAATTCCAATAAAAATATACCCACTAA (R), GGATT-
GAAATTTAGGTTGAT (Seq); COL9A1_3 TGAGGGT-
TAAAAGTAAAGGGAGAG (F), TTTCCCCTA-
TAAATCCCTCCTT (R), GGGAGAGAATTAGAGGTATT
(Seq); MMP13_1 AATTAGTATTAAGTTTTTTTTTATG-
GAAGT (F), TTCAACAAAATCTCAAAACCCATCTAA (R),
AAATTTTTTTTTTTTTACCTTCTAT (Seq1),
CTCAAAACCCATCTAAC (Seq2); MMP13_2 ATGGGTTTT-
GAGATTTTG (F), ACCCCTAAATACATCTTAAATA (R),
CAATCACTTAAAAATAAACATACTT (Seq1), AATAA-
TACCTAAAAACTATTATC (Seq2); IL1B_1 ATGGAAGGG-
TAAGGAGTAGTAA (F), CCCACATATACTAAATTTAAA-
CATTCTT (R), ATACTAAATTTAAACATTCTTCTA (Seq);
IL1B_2 ATGAAGATTGGTTGAAGAGAATTTTAGA (F),
ATTTCTCAACCTCCTACTTCTACTTTTAA (R), ATTTTA-
GAGTAGTTTGTTGTG (Seq); Osteocalcin_1 AG-
TAGGTTGTTTTTGGTGATTTAT (F), CCAACTATCTCA-
CAACCTATAATTTC (R), GGTTGTTTTTGGTGATTTA
(Seq); Osteocalcin_2 AGGTAGTTTGTTGTGGGTGTAGTT
(F), CCCCACCTCCATTAACTTTAA (R),
GTTTGTTGTGGGTGTAGT (Seq).
Immunohistochemistry
Whole femurs were fixed in 95% ethanol, embedded in paraffin
wax and sectioned at 6 mm. Permeabilisation with 0.1% Triton X-
100 and pronase enzymatic digestion for COL9A1 were
employed. Endogenous peroxidase activity was quenched with
Figure 6. Changes in DNMT1 expression in HFBCs and adult
chondrocytes. Relative expression of DNMT1 during chondrocyte
evolution. Levels of DNMT1 were measured by qRT-PCR.
doi:10.1371/journal.pone.0054957.g006
Figure 7. Relative expression of TET1 in HFBCs cells. A. Levels of TET1 were measured by qRT-PCR in comparison with healthy chondrocytes. B.
Correlation of TET1 with sample age.
doi:10.1371/journal.pone.0054957.g007
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3% H2O2, sections were blocked with 1% bovine serum albumin
(BSA) in PBS and incubated overnight at 4uC with primary
antibody in 1% BSA (iNOS (BML-SA200, Enzo Life Sciences,
Inc., PA), COL9A1 (ab75807, Abcam, UK), MMP13 (ab39012,
Abcam, UK), IL1B (AF-201-NA, R&D Systems, Inc., MN) and
STRO-1 (hybridoma supernatant, Dr J Beresford, University of
Bath). Sections were washed with PBS and incubated for 1 hour
with biotinylated secondary antibody. Avidin-biotin method linked
to peroxidase and 3-amino-9-ethylcarbazole (AEC) and counter-
staining with 1% alcian blue was used to visualize, positive staining
appears reddish-brown. Appropriate isotype and secondary
antibody only controls were used to confirm specific staining.
Virtual digital slides were acquired using a dotSlide system
(Olympus) and analysed with OlyVIA software (2.4).
Statistical Analysis
Data is expressed as the mean 6 SD. Statistical analysis was
performed using SPSS software, version 17.0 (SPSS, Chicago, IL)
where Mann-Whitney 2-tailed U test was used to compare
between groups or ANOVA where it was necessary, and
Spearman’s rank correlation coefficient was used for correlation
studies. P values less than 0.05 were considered significant.
Results
iNOS Gene Expression Correlates with Loss of
Methylation during Fetal Femur Development
The human iNOS promoter (sparse CpG promoter) has 7 CpG
sites within the 1,400-bp sequence upstream of exon 1 and 6 CpG
sites within the exon 1 (GenBank accession No. AF017634)
(Figure 1A); the transcription start site was located 30 bp
downstream of a TATA box [20]. In activated chondrocytes,
iNOS expression is known to be significantly higher than in healthy
chondrocytes [21]. However, a significant increase in iNOS
expression from HFBCs to adult healthy chondrocytes was
observed (Figure 1B). This significant increase correlated with a
significant loss of methylation of CpG sites localized near the
transcription start site of iNOS gene. The CpG sites in the initiation
region of the first exon (+13, +33 and +37), were largely
unmethylated in normal and OA patients but, critically, increased
methylation was observed in HFBCs (Figure 1C). Furthermore,
the degree of methylation was inversely correlated to foot length
and, thus, to the age of the sample (CpG sites +13, +33 and +37
mean R=0.87) (Figure 1D). However, immunohistochemical
analysis demonstrates that the majority of cells from fetal femurs
produce iNOS (Figure 1E–H). Although iNOS distribution was
observed to change with the age of the sample; in tissue samples
from 7–8 WPC fetus (n = 8), iNOS displayed a tissue wide
distribution (Figure 1E–F). However, in samples from 8.5–9 WPC
fetus (n = 6), iNOS staining was enhanced with localisation limited
to the superficial area (Figure 1G–H).
COL9A1 Gene Expression Correlates with Loss of
Methylation during Fetal Femur Development
High levels of COL9A1 expression were found in all the HFBCs
samples analysed (59.40639.55, n = 6) (Figure 2A). COL9A1
expression levels were significantly correlated with fetal foot length
(R= 0.84) (Figure 2B).
The human COL9A1 promoter (sparse CpG promoter) contains
8 CpG sites in the 1,000-bp sequence upstream of exon 1
(GenBank accession No. AF036110), relative to the transcriptional
start site (+1) [22] (Figure 2C). In general, methylation levels in all
CpG sites in the COL9A1 promoter region were inversely
correlated with foot length and developmental age; i.e. the oldest
fetal sample analysed displayed the lowest percentage of CpG site
methylation (Figure 2D).
Immunohistochemical analysis showed that the majority of cells
from fetal femurs stained positively for COL9A1 (Figure 2E–H).
Indeed, COL9A1 distribution was observed to change with the
age of the sample; in tissue samples from 7–8 WPC fetus,
COL9A1 staining was weak with widespread distribution
throughout the tissue (Figure 2E–F). In contrast, in older samples
from 8.5–9 WPC fetus, COL9A1 staining was considerably
stronger and was typically localised to the proximal and distal
heads (Figure 2G–H) of the fetal femur.
MMP13 Gene Expression does not Correlate with Loss of
Methylation during Fetal Femur Development
The human MMP13 promoter (sparse CpG promoter) has 7
CpG sites in the 400-bp sequence upstream of exon 1 (GenBank
accession No. NG021404); the transcription start site is located 22-
bp upstream of the ATG start codon [23] (Figure 3A). Substantial
expression of MMP13 was detected in HFBCs samples
(354.26254.2, n= 7) (Figure 3B). Indeed, expression significantly
correlated with femur length (Figure 3C). However, this significant
increase in gene expression is not correlated with loss of
methylation in any of the CpG sites inside the promoter
(Figure 3D), in contrast to our observations for iNOS and COL9A1.
Immunohistochemical analysis indicated that a considerable
proportion of cells from fetal femurs produce MMP13 (Figure 3E–
I) with MMP13 expression noted to alter with the age of the
sample. Thus in a younger tissue sample (from 7–8 WPC),
MMP13 staining was typically weak and widespread in distribu-
tion across the tissue (Figure 3E–F). However, in older fetal
samples (from 8.5–9 WPC), MMP13 staining was significantly
stronger and observed to be predominantly distributed in the
diaphysial centre, specifically in the distal part of the bone
(Figure 3G–I).
IL1B Gene Expression does not Correlate with Loss of
Methylation during Fetal Femur Development
No significant expression of IL1B was detected in HFBCs
compared with healthy adult chondrocytes (Figure 4A). The
human IL1B promoter (sparse CpG promoter) has 7 CpG sites in
the 900-bp sequence upstream of exon 1 and 1 CpG site within
exon 1 (GenBank accession No. AY137079) (Figure 4B); the
transcription start site was located 31 bp downstream of a TATA
box [24]. CpG sites within this proximal promoter region did not
demonstrate a significant correlation between methylation levels
and the size of the examined sample (Figure 4C). Interestingly at
the CpG site located 299 base pairs upstream of the coding start
site, a significant correlation between methylation levels and the
size of the fetal femur sample was observed only in uncultured
samples (R= 0.80). We have previously reported that this position
is a crucial CpG site in the epigenetic induction of IL1B in OA
chondrocytes [12,13].
Immunohistochemical analysis showed there was no significant
expression of IL1B (Figure 4D–G). IL1B staining was only
detectable in tissue samples from 7–8 WPC fetus, although IL1B
staining was weak and observed to be distributed throughout the
tissue (Figure 4D–E).
Osteocalcin Promoter Region Methylation
The human Osteocalcin promoter (sparse CpG promoter) has
10 CpG sites within the vitamin D response element [25].
Assessment of methylation status of this region in human
embryonic stem cells (hESCs) revealed a hypermethylated state,
Fetal Femur Epigenetic Regulation
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consistent with a lack of osteocalcin expression (data not shown),
and epigenetic silencing via methylation. Similarly, DNA isolated
from fetal femur explants was hypermethylated at each CpG site
investigated. Previously we have reported osteocalcin expression in
HFBCs only when cells are incubated in osteogenic conditions
[11]. However, at CpG sites 572, 559, 517 and 468 base pairs
upstream of the osteocalcin start site, methylation was significantly
lower for fetal femur DNA than hESC DNA (Figure 5A).
Significant demethylation was evident between the fetal and
adult developmental stages. Methylation levels of CpG sites 572,
559, 541, 517, 514, 476, 468, 457 and 422 base pairs upstream of
the coding start site were statistically lower for uncultured STRO+
adult skeletal stem cells compared to HFBCs indicating demeth-
ylation at a developmental stage between fetal and adulthood.
However, osteocalcin RNA expression was undetectable in
STRO+ adult skeletal stem cells indicating that demethylation
occurs prior to induction of osteocalcin expression. In all instances,
culture of STRO+ adult skeletal stem cells resulted in further
demethylation leading to a hypomethylated state regardless of
osteocalcin expression (Figure 5A).
On examination of the STRO+ and STRO- fractions, it was
observed that three CpG sites (541, 517 and 514 base pairs
upstream of the coding start site) displayed significantly greater
methylation in STRO- cells (Figure 5B).
Immunohistochemical analysis demonstrated that a consider-
able proportion of cells from fetal femurs produce STRO-1
(Figure 5C–E). STRO-1 staining was typically weak in the
proliferating chondrocyte population with localisation limited to
the superficial area (Figure 5D); however, in the hypertrophic
chondrocyte population, STRO-1 staining was significantly
stronger (Figure 5E).
Decreased DNMT1 Expression in Adult Chondrocytes
qRT-PCR was used to determine whether decreased expression
of DNMT1 contributed to the observed loss of DNA methylation
in chondrocytes from adult cartilage. DNMT1 expression in
healthy chondrocytes was observed to be almost half that of
HFBCs (Figure 6). Additionally, DNMT1 expression in OA
chondrocytes from the surface zone was less than half that
observed in control chondrocytes from patients with femoral neck
fracture (Figure 6), as it had been previously shown [13]. DNMT1
expression levels were found to be independent of fetal sample age
(R= 0.06).
TET Proteins in Fetal Cells
TET1-3 expression was analysed by qRT-PCR. However, only
TET1 showed higher expression in HFBCs compared to human
adult chondrocytes (3.865.0 versus 1.160.8; n= 9) (Figure 7A).
However this difference was not statistically significant (P = 0.15),
and TET1 expression was observed to display a very weak
correlation to fetal age (Figure 7B).
Discussion
Epigenetic marks, including CpG methylation, are generally
stable in somatic cells; however, during at least two developmental
time periods, the epigenome undergoes extensive epigenetic
programming [26]. These critical windows of development include
gametogenesis as well as early pre-implantation embryos [3]. The
pattern of distribution of methyl groups in DNA differs depending
on cell type and confers a cells specific identity on DNA during
cellular differentiation and organogenesis. This is an innate and
highly programmed process [27] and an understanding of the
underlying epigenetic mechanisms that regulate gene expression in
bone development provide important possibilities in tissue repair.
The human fetal femurs used in these studies contain
predominantly epiphyseal chondrocytes surrounded by a peri-
chondrium/periosteum consisting of an outer fibroblastic layer
and an inner layer of non-committed mesenchymal stem cells, the
latter capable of differentiating either along the chondrogenic,
osteogenic or adipogenic lineages [11]. A first biological charac-
terization of HFBCs has already been reported indicating that
these cells have an enhanced capacity to proliferate compared with
human osteoblasts and a higher capacity to differentiate in vitro
into bone cells compared with mesenchymal cells [28]. Further-
more, other authors suggest that cells taken before 8 weeks of
development represent a predominantly more primitive cell
population [29]. To test the utility of HFBCs to study the
epigenetic mechanisms implicated on bone development, we have
examined the influence of DNA de-methylation on gene
expression, with emphasis on physiological genes vital for bone
biology (iNOS and COL9A1) and, catabolic/pathologic genes
important for bone modulation and remodelling as well
(MMP13 and IL1B). These genes, iNOS, COL9A1, MMP13 and
IL1B were selected as key genes linked to OA; in this regard we
have already published on the importance of IL-1B and MMP13
in the context of cartilage and OA [12,13,14], and sought to
extend these observations to our understanding during fetal
development and the role of epigenetics. In all studies, human fetal
femur derived skeletal cells were used directly after digestion as
culture conditions alone can induce de-methylation.
iNOS plays an important role in various cell systems including
bone, where it has a dual role. Evidence from gene-knockout
studies indicates that bone formation and resorption are regulated
by NO [30]. Furthermore, a number of studies have indicated the
active involvement of NO in bone healing [31,32,33,34], bone
development [35,36,37,38,39] and bone loss [40,41]. Thus tight
regulation of iNOS would be expected for this gene, and we
observed such an exquisite epigenetic regulation of iNOS. The
increase in expression levels correlated with loss of methylation in
specific CpG sites localized at the transcription start site. Similarly,
A2(1) collagen transcription is inhibited by methylation sites within
the first exon at the initiation site of transcription [42]. Others
have reported that effective gene suppression was observed when
promoters were methylated in the pre-initiation domain [43];
methylation of coding regions are common in mammalian genes
and reportedly improve genome stability [44]. In the context of
bone, Delgado-Calle and collaborators have recently demonstrat-
ed that the methylation status of CpG dinucleotides within the
proximal promoter plays an important role in the regulation of
SOST (encodes Sclerostin protein) expression, impairing its
expression in osteoblasts and other extraskeletal cells and
permitting expression in osteocytes [45].
In HFBCs, in which we observed higher levels of methylation
but no mRNA expression, inhibition of DNA methylation by 5-
aza-29-deoxycytidine (5-aza) and trichostatin A (TSA) treatment,
was not sufficient to induce iNOS expression; similar results were
also recorded for adult chondrocytes (data not shown).
Type IX collagen, although a minority molecule in hyaline
cartilage, is a key component acting as a molecular bridge between
cartilage collagen fibrils and other matrix components, possibly
proteoglycans [46,47]. It has been shown that the lack of collagen
IX seriously affects growth plate organization, especially in young
animals [48]; furthermore, COL9A1 deregulation is an accepted
marker of OA [49]. Tight regulation is considered to occur during
bone development and the current results are consistent with
epigenetic control during fetal development. Critically a sequential
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loss of methylation was noted to correlate with an increase in gene
expression. Further experiments were conducted and, after
treatment with 5-aza plus TSA, COL9A1 expression correlated
with DNA methylation (Imagawa et al., manuscript in prepara-
tion).
Bone development requires a complex remodelling of the
extracellular matrix, and this is predominantly mediated by matrix
metalloproteinases (MMPs) [30]. MMP13 is a potential target for
NO regulation in bone development, with Cbfa-1 (RUNX2) a
mediator of NO action [30]. We observed a spatial and sequential
MMP13 expression, however this was independent of the
methylation status of MMP13 promoter. Thus it would appear
genes involved in normal femur development are epigenetically
regulated during fetal femur development, however expression of
catabolic genes such as MMP13 or IL1B are independent of DNA
methylation. Nevertheless, previous experiments within our group
showed interesting results in chondrocytes with 5-aza and TSA
capable of inducing IL1B expression [13], and MMP13 (Hashi-
moto et al., manuscript in preparation); however, in HFBCs no
changes in expression were detected for these genes (data not
shown).
Furthermore, the reduction in DNMT1 expression levels
observed in adult chondrocytes compared to HFBCs is in
agreement with the increment of expression of certain vital genes
for bone development.
Recently, it has been demonstrated that oxidation of 5-
methylcytosine to 5-hydroxymethylcytosine by TET family
hydroxylases may also participate in active DNA demethylation
[50,51]. Specifically, TET1 is involved in embryonic stem cell
(ESC) maintenance and inner cell mass (ICM) cell specification,
possibly by participating in DNA demethylation [52]. In this
regard, we observed lower TET1 expression levels in adult
chondrocytes in comparison to HFBCs samples, where an active
de-methylation process is in progress. Conversion of 5-methylcyt-
osine to 5-hydroxymethylcytosine may facilitate passive DNA
demethylation by excluding the maintenance DNA methyltrans-
ferase DNMT1, which poorly recognizes 5-hydroxymethylcytosine
[53]. Interestingly, it has been postulated that the balance between
hydroxymetylation and methylation in the genome is inextricably
linked with the balance between pluripotency and lineage
commitment [54].
Osteocalcin is a non-collagenous protein secreted by osteoblasts
and is therefore a specific marker for osteoblast activity [55]. Cells
isolated from 12–14 WPC fetal femurs present characteristics of
advanced osteoprogenitors compared with human mesenchymal
stem cells isolated from bone marrow [29]. The STRO+ fraction
of adult bone marrow contains a population of skeletal stem cells
with osteogenic, chondrogenic and adipogenic differentiation
potential [17]. These cells are of potential interest for therapeutic
use in bone tissue engineering. It has been reported that reduced
DNA methylation of CpG islands in the osteocalcin and
osteopontin genes is associated with osteogenic differentiation
[56,57]. We did not detect osteocalcin expression but observed
developmental stage-dependent demethylation suggesting that
demethylation alone does not regulate osteocalcin expression but
that methylation can prevent expression. However, the fact that
certain CpG sites displayed significantly greater methylation in
STRO- cells appears to be no coincidence given that the STRO+
fraction has osteogenic potential and thus the potential to express
osteocalcin upon differentiation. Mirmalek-Sani and collaborators
demonstrated that HFBCs expressed accelerated osteogenesis
evidenced by reduced culture periods and higher levels of bone
markers such as RUNX2, alkaline phosphatase (ALP) and
COL1A1 compared with human bone marrow derived mesen-
chymal cells, suggesting that HFBCs are more advanced in their
osteogenic program [11]. Montjovent and colleagues also reported
enhanced ALP and mineralisation activity compared to adult
mesenchymal populations [28]. Interestingly, HFBCs and HMSCs
failed to express cartilage markers such as SOX9 and COL2A1.
We have performed preliminary experiments using adult human
osteosarcoma osteoblast-like bone cell lines (MG63 and Saos-2
unpublished observations). In these studies the human osteoblast
like cell lines failed to express our genes of interest. Furthermore,
the lack of expression was observed to correlate with high levels of
methylation of most CpG sites of these promoters.
To date, there is a paucity of information regarding the role of
DNA methylation in the differentiation of adult human skeletal
cells, although some recent studies suggest that it is involved in the
regulation of a number of bone genes, as well as in bone cell
differentiation [56,58,59]. Previously, we have shown that
monolayer cultures of human bone marrow stromal cells treated
for 3 days with the 5-aza or TSA, followed by culture in the
absence of modifiers displayed distinct phenotypic changes. 5-aza
stimulated osteogenic differentiation (evidenced by enhanced ALP
activity, increased Runx-2 expression in monolayer, and increased
osteoid formation in 3D cell pellets) whilst pellet cultures of human
skeletal cells in chondrogenic media with TSA enhanced cartilage
matrix formation and chondrogenic structure [60].
Interestingly, it has recently been published that osteoblasts and
osteocytes have opposite DNA methylation profiles in the ALP
promoter, which is hypomethylated in osteoblasts and hyper-
methylated in osteocytes, suggesting that DNA methylation is
inhibiting ALP expression in the latter [61].
In fetal bone femurs, relatively small numbers of differentiated
osteoblasts were present along the central diaphysis, as indicated
by the presence of the first bone collar. The cells that grew out
from the dissected explants during culture could thus theoretically
be derived from the cut edges of the epiphysis (early chondrocytes)
or from the perichondrium (fibroblastic or mesenchymal stem
cells). Given epiphyseal chondrocytes were by far the most
frequent cell type present in the fetal femurs and as most
outgrowth was observed from the cut edges, it is probable that the
starting cells were early chondroprogenitor and mesenchymal
progenitor populations [11]. Recent experiments in our group
analysed DNA methylation status of genes over- or under-
expressed in a sub-set of samples. These studies found that
100% of over-expressing samples but just 43% of under-expressing
samples had decreased promoter methylation [62].
Conclusions
Here we show that the regulation of genes involved during
normal bone development are controlled by epigenetic mecha-
nisms, specifically loss of methylation in crucial CpG sites of their
proximal promoters. In conclusion, these findings demonstrate the
role of epigenetic regulation, specifically DNA methylation, in
bone development, informing and opening new possibilities in
development of strategies for bone repair and tissue engineering.
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